| Name | Tenovin-1 |
| Description | Tenovin-1 inhibits protein-deacetylating activities of SirT1 and SirT2 and protects against MDM2-mediated p53 degradation, which involves ubiquitination. |
| Cell Research | Cell viability isdetermined by trypan blue exclusion, Giemsa staining, or MTT assays.(Only for Reference) |
| In vitro | Tenovin-1 (10 μM) protected p53 from mdm 2-mediated degradation, but had little effect on p53 protein synthesis. When applied to p53-expressing tumor cells, Tenovin-1 inhibited cell growth and induced apoptosis.Tenovin-1 is a p53 activator and increased the amount of p53 protein within 2 h of treatment.Tenovin-1 did not affect p53 mRNA levels. |
| In vivo | Tenovin-1 (10 μM) protected p53 from mdm 2-mediated degradation, but had little effect on p53 protein synthesis. When applied to p53-expressing tumor cells, Tenovin-1 inhibited cell growth and induced apoptosis.Tenovin-1 is a p53 activator and increased the amount of p53 protein within 2 h of treatment.Tenovin-1 did not affect p53 mRNA levels. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 9.2 mg/mL (24.9 mM), Sonication is recommended.
|
| Keywords | Tenovin-1 | Tenovin1 | Sirtuin | protein-deacetylating | p53 | MDM-2/p53 | MDM2 | Inhibitor | inhibit | Dihydroorotate Dehydrogenase | DHODH | degradation | Autophagy | acetylation |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Nicotinamide riboside malate | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | Paeonol | Naringin | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Reprogramming Compound Library | Glycometabolism Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Autophagy Compound Library | Inhibitor Library | NO PAINS Compound Library | PPI Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
